Academic medical center
Appears in 1 story
Conducted the Phase 1a trial
A single infusion of a CRISPR gene-editing therapy kept LDL cholesterol about 52% lower and triglycerides about 48% lower for a full year. The results, from a 15-patient trial, are the longest durability data yet for in vivo CRISPR in heart disease. They were presented at the European Society of Cardiology meeting and published in the New England Journal of Medicine.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
